New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases with progressive weakness of skeletal and respiratory muscles, leading to significant disability. The disorder is caused by mutations in the survival motor neuron 1 (<i>SMN1</i>) gene and a consequent de...
Main Authors: | Sonia Messina, Maria Sframeli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/7/2222 |
Similar Items
-
2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia
by: Fahad A. Bashiri, et al.
Published: (2021-05-01) -
INNOVATIVE THERAPIES IN GENETIC DISEASES: SPINAL MUSCULAR ATROPHY
by: Elena-Silvia Shelby, et al.
Published: (2021-06-01) -
Review of therapeutic options for spinal muscular atrophy
by: Singh Arun, et al.
Published: (2021-01-01) -
Spinal muscular atrophy - onasemnogene abeparvovec and other therapeutic options
by: Aleksandra Alicja Majchrzak-Celińska, et al.
Published: (2020-02-01) -
Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment
by: Alisha Monnette, et al.
Published: (2021-01-01)